Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.09T
Market cap1.09T
Price-Earnings ratio
40.25
Price-Earnings ratio40.25
Dividend yield
0.56%
Dividend yield0.56%
Average volume
2.49M
Average volume2.49M
High today
$1,214.99
High today$1,214.99
Low today
$1,155.27
Low today$1,155.27
Open price
$1,186.03
Open price$1,186.03
Volume
3.40M
Volume3.40M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$725.31
52 Week low$725.31

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,162.50, giving the company a market capitalization of 1.09T. It carries a P/E multiple of 40.25 and pays a dividend yield of 0.56%.

On 2026-09-30, Eli Lilly(LLY) stock traded between a low of $1,155.27 and a high of $1,214.99. Shares are currently priced at $1,162.50, which is +0.6% above the low and -4.3% below the high.

The Eli Lilly(LLY)'s current trading volume is 3.4M, compared to an average daily volume of 2.49M.

During the past year, Eli Lilly(LLY) stock moved between $725.31 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $725.31 at its lowest and $1,292.65 at its peak.

LLY News

Investor's Business Daily 3h
Why These S&P 500 Stocks Are Earning The Biggest EPS Upgrades

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Amazon In New Base 9/30/2026 Among the best stocks in earnings performance, highly rated...

Why These S&P 500 Stocks Are Earning The Biggest EPS Upgrades
Benzinga 4h
Eli Lilly Data Shows Retatrutide Promotes Weight Loss Over Eighty Weeks

Pharmaceutical giant Eli Lilly and Co. (NYSE:LLY) reported positive data from two late-stage clinical trials, showcasing substantial progress in treatments for...

Eli Lilly Data Shows Retatrutide Promotes Weight Loss Over Eighty Weeks
TipRanks 5h
Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly And Company (LLY) is running a Phase 2b study called “A Study of Cla...

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

Nasdaq 5h
Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market.

Key Points TRIUMPH-2 contains retatrutide, a triple agonist weight loss drug. Triple-agonist drugs attempt to suppress appetite, lower blood sugar, and increa...

Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market.
TipRanks 6h
Eli Lilly Stock Moves Higher on Positive Trial Results for Zepbound Combo

Eli Lilly’s (LLY) stock is rising on Sept. 30 after the pharmaceutical giant reported that “EloraTZP,” a combination regimen containing its popular weight-loss...

Nasdaq 6h
Lilly's EloraTZP Delivers Weight Loss Results In Phase 2b Trial

(RTTNews) - Eli Lilly and Company (LLY) said on Wednesday that its investigational EloraTZP combination of eloralintide and tirzepatide delivered substantial we...

Lilly's EloraTZP Delivers Weight Loss Results In Phase 2b Trial
MarketWatch 7h
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

In the race to come up with newer and better weight-loss drugs, Eli Lilly appears to have found a powerful combination. The pairing of a promising new drug wit...

Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
TipRanks 7h
Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

Eli Lilly (LLY) announced “positive” results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP. Eloralintide alone reduced body weight by up...

Reuters 7h
Experimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters

...

Experimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
CNBC 7h
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Lilly signage during a groundbreaking ceremony for Eli Lilly and Company's pharmaceutical manufacturing campus at Generation Park in Houston, Texas, US, on Mond...

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.